Bio3 Research And Creabilis Therapeutics Sign Research Agreements With Cephalon, Inc. Research Will Focus On Potential New Treatments For Psoriasis And Restenosis

COLLERETTO GIACOSA (Turin), Italy, and MILAN, Italy--(BUSINESS WIRE)--Dec. 1, 2005--Bio3 Research S.r.l., and Creabilis Therapeutics S.p.A. announced agreements with Cephalon, Inc. to evaluate the research compound K252a for its potential to topically treat psoriasis and for potential use in the prevention and treatment of restenosis. Creabilis Therapeutics owns patent applications covering K252a-based products for the treatment of psoriasis.